Zeta PTEN Antibody. Zeta’s recombinant rabbit antibody recognized PTEN, a tumor suppressor that plays a role in cell proliferation, apoptosis, and migration. PTEN is mutated in a large number of cancers, including sporadic brain, breast, endometrial, kidney, and prostate cancers. PTEN is one of the most commonly lost tumor suppressors in human cancer, acting as negative regulator of the P PI3K/AKT signaling pathway, where loss of PTEN activity causes an upregulation in the AKT pathway.
PTEN (phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase) contains a tensin-like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases.
Immunohistochemistry using Zeta’s PTEN antibody can be used to assess PTEN status in FFPE samples, to detect loss of the PTEN gene. PTEN hamartoma tumor syndrome (PHTS) is a spectrum of human pathologies that result from mutations in PTEN. PTEN mutations have been associated with several syndromes including Cowden, Bannayan-Riley-Ruvalcaba, Lhermitte-Duclos and Proteus-like. Loss of nuclear PTEN expression in adenomatous thyroid nodules is sensitive and specific for Cowden syndrome. Approximately 10% of benign melanocytic nevi demonstrate some PTEN loss. Between 10% and 30% of melanomas harbor a PTEN aberration. Loss of cytoplasmic PTEN may distinguish intraductal prostatic carcinoma from high grade PIN.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.